Alps Advisors Inc Mersana Therapeutics, Inc. Transaction History

Alps Advisors Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.06 - $3.91 $5,129 - $18,920	4,839 Added 5.76%	88,919 $112,000
Q2 2023 Aug 14, 2023	BUY	$3.08 - $9.55 $39,759 - $123,280	12,909 Added 18.14%	84,080 $276,000
Q1 2023 May 10, 2023	BUY	$4.0 - $7.02 $13,740 - $24,113	3,435 Added 5.07%	71,171 $292,000
Q4 2022 Feb 14, 2023	BUY	$5.65 - $7.86 $382,708 - $532,404	67,736 New	67,736 $396,000

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $192M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.